Tuesday, July 30, 2013
Cubist to buy Trius Therapeutics, Optimer Pharma for up to $1.62 billion
(Reuters) - Cubist Pharmaceuticals Inc said it would buy Trius Therapeutics Inc and Optimer Pharmaceuticals Inc for up to $1.62 billion to boost its antibiotics portfolio.
Cubist said it would buy all outstanding shares of Optimer for a total of $15.75 per share in cash, including contingency payments. The offer represents a premium of 18 percent on Tuesday's closing price.
Cubist said it would pay a total of $15.50 per share for Trius, including contingency payments. The offer represents a premium of 32 percent to the stock's closing price on Tuesday.
(This story is corrected in paragraphs 2 and 3 to say the per-share offers include contingency payments)
(Reporting By Vrinda Manocha in Bangalore; Editing by Maju Samuel)
This entry passed through the Full-Text RSS service — if this is your content and you're reading it on someone else's site, please read the FAQ at fivefilters.org/content-only/faq.php#publishers. Five Filters recommends: 'You Say What You Like, Because They Like What You Say' - http://www.medialens.org/index.php/alerts/alert-archive/alerts-2013/731-you-say-what-you-like-because-they-like-what-you-say.html
